Abstract:Objective To evaluate the clinical effect of post bladder sparing surgery intra-arterial chemotherapy combined with intravesical chemotherapy for the treatment of T1G3 bladder urothelial carcinoma. Methods Seventy-four T1G3 bladder cancer patients were enrolled in this study.After bladder sparing surgery,22 patients received intra-arterial chemotherapy combined with intravesical chemotherapy,while the other 52 patients were treated with intravesical chemotherapy only.There was no significant difference between the 2 groups in sex,age,the size and number of bladder tumor and newly diagnosed cases (P ＞0.05).Twenty-two patients were treated with intra-arterial chemotherapy of piarubicin or epirubicin (40 -60 mg) + cisplatin (60 -80 mg) 2 or 3 weeks after bladder sparing surgery,3 times as a cycle,repeat every 4 - 6 weeks.All the patients received the same protocol of intravesical chemotherapy.With a median follow-up of 32 months,effects of combination therapy group were compared with intravesical chemotherapy group in the aspects of tumor-specific death rates,recurrent rate,progressive rate,recurrent interval and the adverse reactions. Results The tumor-specific death rates of combination therapy group and intravesical chemotherapy group were 0％ (0/22) and 13.5％ (7/52),respectively.There was no difference between the 2 groups (P =0.096).The recurrent rates were 13.6％ (3/22) and 46.2％ ( 24/52 ) ； The progressive rates were 0％ (0/22) and 21.2％ (11/52).There were significant differences between the 2 groups in recurrent rate (P =0.000) and progressive rate (P =0.048 ).The recurrent intervals of the 2 groups were 15 months and 6.5 months.During the interval of intra-arterial chemotherapy cycle,12 patients suffered 1 -2 degree nausea and vomit,2 patients suffered hypoleukemia,2 patients suffered neutropenia,4 patients'liver function was impaired and 1 patient's renal function was impaired.All the adverse reactions were minimal and reversible. Conclusions Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing T1 G3 bladder cancer from recurrence and metastasis after bladder sparing surgery.The adverse reactions of this protocol were minimal and reversible.

Efficacy of salvage intra-arterial chemotherapy after transurethral resection of bladder tumor for muscle invasive bladder cancer

Combined Modality Therapy Following Bladder Conservation Surgery for Bladder Cancers

Intra-Arterial Chemotherapy for Muscle-Invasive Bladder Cancer Following Transurethral Resection

The clinical study of intra-arterial chemotherapy followed by bladder-preserving surgery for high-risk non muscle-invasive bladder cancer

Clinical efficacy and surgical skills of transurethral resection of bladder tumor in the treatment of non-muscle invasive bladder cancer

The Clinical Analysis of Transurenthral Resection Therapy for Muscle Invasive Bladder Cancer

The outcome of bladder-sparing surgery combined with intra-arterial chemotherapy for invasive bladder cancer

Single-dose intra-arterial infusion chemotherapy for refractory bladder cancer after transurethral resection of bladder tumor: Report of 12 cases

Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer.

Effect of Post Bladder Sparing Operation Intra-Arterial Chemotherapy Combined with Intravesical Chemotheraoy for the Treatment of T1G3 Bladder Urothelial Carcinoma

Preliminary results of intra-artery chemotherapy for T1G3 bladder cancer

Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer

Combinations of Intra-Artery Chemotherapy and Bladder-Preserving Resection for Primary T1G3 Bladder Cancer

Transurethral Electric Resection Plus Arterial Catheterization Chemotherapy for T2a Bladder Carcinoma

A Role of Multimodality Bladder-Preserving Therapy in Patients with Muscle-Invasive Bladder Cancer Plus Hydronephrosis with or Without Pelvic Nodal Involvement.

TURBT for the Treatment of Invasive Bladder Cancer

Organ Preservation for Muscle-Invasive Bladder Cancer by Transurethral Resection

Effects of Intravenous Chemotherapy after TURBT for High-Risk Nonmuscle Invasive Bladder Cancer: Results of a Retrospective Study

Effectiveness of Neoadjuvent Chemotherapy with Gemcitabine and Cisplatin for Muscle Invasive Bladder Carcinoma

Combinations of Internal lliac Arterial Chemotherapy and Bladderpreserving Resection for Local Invasive Bladder Cancer

Intra-arterial Chemotherapy for Preventing the Recurrence of Invasive Bladder Cancer after Operation